Over the past decade, the use of prescription drugs has skyrocketed, with nearly half of all Americans now taking at least one prescription drug.([@R1]) Accompanying the increased prevalence of drug use is a high burden of adverse drug reactions (ADRs), which account for approximately 100,000 deaths and 2.2 million serious health effects annually.([@R2]--[@R4]) QT interval (QT) prolongation, which can trigger fatal ventricular arrhythmias, is a long-recognized adverse effect([@R5]) of numerous common medications, such as antipsychotics, antibiotics, antiarrhythmics, and antihypertensives.([@R6]) Within the past ten years, QT prolongation has represented the most common cause for withdrawal of a drug from the market (or relabeling) after approval by the U.S. Food and Drug Administration (FDA).([@R7], [@R8]) However, drug-induced QT prolongation remains difficult to predict.([@R9])

Genetic variants are known to mediate both pharmacokinetic and pharmacodynamic processes, thereby playing a major role in drug response. ([@R10]) Pharmacogenomics, which evaluates the role of genetics in drug response, offers a promising avenue for understanding variation in drug response,([@R11]) illuminating novel pathways, informing drug development and selection,([@R12]--[@R14]) optimizing dosing regimens,([@R15]--[@R19]) and avoiding ADRs.([@R20]--[@R22]) QT is highly heritable (35--40%).([@R23]--[@R27]) Previous pharmacogenomics studies of drugs associated with QT prolongation, including thiazide diuretics, a common antihypertensive therapy used by over a quarter of the U.S. hypertensive population,([@R28]) identified multiple loci associated with anti-hypertensive response and ADRs.([@R29]--[@R34]) Furthermore, thiazide diuretics are used unequally across race/ethnic groups in the U.S., with approximately 10% of Hispanic/Latinos, 13% of European Americans, and 23% of African Americans taking a thiazide diuretic.([@R28], [@R35], [@R36]) Therefore, the pharmacogenomics of thiazide-induced QT prolongation represents an excellent but understudied candidate for pharmacogenomic inquiry.

We previously examined evidence for common single nucleotide polymorphisms (SNPs) that modified the association between thiazide use and QT and failed to identify any genome-wide significant loci (*P*\<5×10^−8^).([@R37]) However, our previous study was limited to European descent populations and cross-sectional analyses, despite many of the contributing studies having longitudinal drug and electrocardiographic data.([@R37]) Here, we expand upon that work, applying recent statistical innovations to leverage longitudinal data and including an additional 44,418 participants of European, African American, and Hispanic/Latino descent to perform the first trans-ethnic genome-wide association study (GWAS) to examine genetic associations that modify the association between thiazides and QT, as well as the component parts of QT (JT interval \[JT\], QRS interval \[QRS\]).

Materials and Methods {#S1}
=====================

Study Populations {#S2}
-----------------

Fourteen cohorts from in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)([@R38]) Pharmacogenomics Working Group (PWG) participated in this analysis, contributing 78,199 participants: European descent (51,601), African American (11,482), and Hispanic/Latino (15,116) participants ([Table 1](#T1){ref-type="table"}, [Supplementary Text](#SD1){ref-type="supplementary-material"}). Among the fourteen cohorts, six (55% of the total population) had repeated measurements of medication use and electrocardiogram (ECG) assessments and contributed longitudinal data to the analysis: Age, Gene/Environment Susceptibility -- Reykjavik Study (AGES), Atherosclerosis Risk in Communities (ARIC) Study, Cardiovascular Health Study (CHS), Rotterdam Study (RS), Multi-Ethnic Study of Atherosclerosis (MESA), and Women's Health Initiative (WHI). The remaining eight cohorts contributed cross-sectional data to the analysis: Framingham Heart Study (FHS), Erasmus Rucphen Family (ERF) Study, Health 2000 (H2000), Health, Aging, and Body Composition (Health ABC), Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Jackson Heart Study (JHS), Netherlands Epidemiology of Obesity (NEO) Study, and Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Study Design {#S3}
------------

Participants with ECG measurements, medication assessment, and genome-wide genotype data were eligible for inclusion. The following exclusion criteria were applied: poor ECG quality, atrial fibrillation detected by ECG, pacemaker implantation, second or third degree atrioventricular heart block, QRS greater than 120 milliseconds (ms), prevalent heart failure, pregnancy, missing ECG, missing medication assessment, missing genotype information, or race/ethnicity other than European descent, African American, or Hispanic/Latino. For studies with longitudinal data, exclusion criteria were applied on a visit-specific basis.

Medication Assessment {#S4}
---------------------

Medication use was assessed through medication inventories conducted during clinic visits, home interviews, or through pharmacy databases ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Six studies captured medication used on the day of the study visit. A further six of the 14 participating cohorts captured medications used one to two weeks preceding ECG assessment. HCHS/SOL ascertained medications used within four weeks preceding ECG measurement, and the RS captured medication used within 30 days preceding ECG assessment. Participants were classified as thiazide diuretic users if they took a thiazide or thiazide-like diuretic in a single or combination preparation, with or without potassium (K)-sparing agents, and with or without K-supplements.

For cross-sectional studies, the number of exposed participants (*N~exposed~*) was defined as the number of participants classified as thiazide users. For studies with longitudinal data, *N~exposed~* was calculated as follows: $$N_{\exp\mathit{osed}} = \sum\limits_{i}{\frac{n_{i}}{1 + \left( {n_{i} - 1} \right)\hat{\rho}}\frac{\#\left\{ {E_{it} = 1} \right\}}{n_{i}}}$$ where n*~i~* is the number of observations for participant *i*, *ρ̂* is an estimate of the pairwise visit-to-visit correlation within participants from a Generalized Estimating Equation (GEE)-exchangeable model that does not contain genetic data, and \#{*E~it~* = 1} is the number of observations for which participant *i* was exposed.([@R39])

ECG Interval Measurement {#S5}
------------------------

QT and QRS were digitally recorded by each participating study using resting, supine or semi-recumbent, standard 12-lead ECGs ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Comparable procedures were used for preparing participants, placing electrodes, recording, transmitting, processing, and controlling quality of ECGs. Studies used Marquette MAC 5000, MAC 12, MAC 1200, or MAC PC (GE Healthcare, Milwaukee, Wisconsin, USA), University of Glasgow (Cardiac Science, Manchester, UK), or ACTA (EASOTE, Florence, Italy) machines. Recordings were processed using one of the following programs (Marquette 12SL, MEANS, University of Glasgow, Digital Calipers, or Health 2000 custom-made software. JT was calculated by the formula: JT=QT−QRS.

Genotyping and Imputation {#S6}
-------------------------

Each study conducted genome-wide genotyping independently using either Affymetrix (Santa Clara, CA, USA) or Illumina (San Diego, CA, USA) arrays ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Sex mismatches, duplicate samples, and first-degree relatives (except in ERF, FHS, HCHS/SOL, and JHS) were excluded. DNA samples with call rates less than 95--98% were excluded, as were SNPs with SNP call rates less than 90--98%, minor allele frequencies (MAF) less than 1%, or that failed Hardy-Weinberg equilibrium. To maximize genome coverage and comparisons across genotyping platforms, genotypes were imputed using HapMap2,([@R40]--[@R42]) 1000 Genomes Phase 1, or 1000 Genomes Phase 3 reference panels.([@R43], [@R44]) Genotypes imputed using build 37 were lifted over to build 36([@R45], [@R46]) to enable comparisons between imputation platforms and results were restricted to SNPs present in HapMap2.

Statistical Analyses {#S7}
--------------------

Genome-wide pharmacogenomic analyses were performed by each cohort independently across approximately 2.5 million SNPs for QT, QRS, and JT separately. Drug-SNP interactions were estimated assuming an additive genetic model, using mixed effect models, GEE, or linear regression with robust standard errors. The analytic model varied based on study design and the availability of longitudinal data ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). All analyses were adjusted for age (years), sex when applicable, study site or region, principal components of genetic ancestry, visit-specific RR interval (ms), and visit-specific QT altering medications defined using the University of Arizona Center for Education and Research on Therapeutics (UAZ CERT) QT-prolonging drug classification.([@R6]) Furthermore, ERF, FHS, and HCHS/SOL incorporated estimates of relatedness into all analyses. Study-specific results were corrected for genomic inflation (λ).

Previous simulations demonstrated that models using robust standard errors underestimate the variance of coefficient estimates for SNPs with low MAFs.([@R39]) To account for this underestimation, corrected standard errors were calculated using a (Student's) *t*-reference distribution.([@R39]) The degrees of freedom (df) for the *t*-reference distribution were estimated using Satterthwaite's method.([@R47]) When cohorts were unable to implement Satterthwaite's method, an approximate df was calculated as twice the cohort- and SNP-specific product of the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and *N~exposed~*. Standard errors were then "corrected" by assuming a normal reference distribution that yielded the *t*-distribution based *P*-values from the beta estimates.([@R39]) Furthermore, because simulations demonstrated that corrected standard errors were unstable when minor allele counts among the exposed were low, a cohort-specific df filter of 15 was applied across all SNPs.([@R39])

For each trait, race-stratified and trans-ethnic betas and corrected standard errors were combined with inverse-variance weighted meta-analysis conducted in METAL.([@R48]) We used a genome-wide significance threshold of *P*\<5×10^−8^ and a suggestive threshold of *P*\<5×10^−6^. However, the assumptions of a fixed-effects meta-analysis do not always hold between race/ethnicities due to differences in patterns of linkage disequilibrium (LD) across ancestral populations, potential allelic heterogeneity, differences in gene-environment and gene-gene interactions, and differences in environmental and lifestyle factors.([@R49], [@R50]) Therefore, trans-ethnic meta-analysis was also conducted using the Bayesian MANTRA approach and a genome-wide threshold of log~10~(Bayes Factor \[BF\])\>6 and a suggestive threshold of log~10~(BF)\>5.([@R51]) Additionally, previous studies have demonstrated the potential to increase power and detect evidence of pleiotropy by conducting multi-trait analysis across correlated traits.([@R52], [@R53]) To examine potential pleiotropy across ventricular depolarization and repolarization, we conducted cross-phenotype meta-analysis combining *t*-statistics across QRS and JT using an adaptive sum of powered score (aSPU) test, which tests for both concordant and discordant associations across some or all of the included traits.([@R54]) The reference distribution for the aSPU test was calculated using 10^8^ simulations.

Genome-wide significant and suggestive meta-analysis results were examined for gene or pathway enrichment. Previous work has shown that it is beneficial to apply multiple methods of gene-set analysis (GSA) when the underlying etiology of the genetic mechanism is unclear.([@R55]--[@R57]) We therefore used two methods of GSA. We performed a multiple regression gene analysis approach followed by a self-contained GSA using gene-level regression as implemented in MAGMA.([@R58]) Post-meta-analysis *P*-values were used as input in the analysis and gene-sets were collected from Ingenuity,([@R59]) Panter,([@R60]) KEGG,([@R61]) and ConsensusPathDB([@R62], [@R63]) and restricted to biologically motivated pathways involved in the following: ion transport and homeostasis, transcription and translation, renal and cardiac development and function, and pharmacokinetic/dynamic pathways. Additionally, we selected all SNPs with *P*\<1×10^−5^ for analysis with DEPICT, which searches for gene, gene-set, and tissue enrichment among 14,461 reconstituted gene-sets, eliminating the need to select candidate gene-sets.([@R64]) To account for multiple testing, we applied a false discovery rate (FDR) threshold of 5% for both GSA approaches.

Statistical Power Simulations {#S8}
-----------------------------

Statistical power to detect drug-SNP interactions using cross-sectional and longitudinal modeling approaches was estimated via simulation studies. Assumptions, which were informed by European ancestry populations, included: (1) 50,000 participants; (2) a two-sided, per-SNP α=5×10^−8^; (3) a mean heart rate-corrected QT (standard deviation)=400 ([@R30]) ms; (4) *N*~exposed~=8,100; (5) a mean drug effect for those with zero copies of the minor allele=5 ms; (6) a mean SNP effect for those not exposed to drug=0 ms; (7) a MAF=0.05 or 0.25; (8) an additive model of inheritance; (9) two study visits for longitudinal simulations; (10) within-person QT correlation=0.80; (11) an attrition rate between visits for longitudinal simulations=0.13; (12) random missingness rate across study visits=0.09; and (13) an independent GEE correlation structure for longitudinal simulations. For longitudinal simulations, drug use was either temporally constant or variable. When variable, drug exposure was assumed to be completely random at both visits.

Results {#S9}
=======

Study Characteristics {#S10}
---------------------

A total of 78,199 participants were included in the analysis, of which 13,730 (18%) were exposed to thiazides ([Table 1](#T1){ref-type="table"}). Thiazide use was most common among African Americans (36%), compared with 16% and 9% among European descent and Hispanic/Latino populations, respectively. Mean age ranged from 40 (FHS) to 75 years (PROSPER) and the percentage of females ranged from 47% (NEO, PROSPER) to 100% (WHI). Average QT was between 389 ms (H2000) and 416 ms (HCHS/SOL).

Genome-Wide Analysis of Thiazide-SNP Interaction and QT Interval {#S11}
----------------------------------------------------------------

Q-Q plots for individual study results, as well as for meta-analyzed results, demonstrated adequate calibration of study specific test statistics ([Supplementary Figures 1--4](#SD1){ref-type="supplementary-material"}). However, the family-based studies (ERF, FHS, HCHS/SOL) showed modest evidence of over-dispersion (λ=1.07 -- 1.16).

No genome-wide significant thiazide-SNP interaction effects were detected in any race/ethnic group ([Figure 1](#F1){ref-type="fig"}). However, suggestive interaction effects (*P*\<5×10^−6^) were found for 22 loci in at least one race/ethnic group: European descent (seven loci), African American (six loci), Hispanic/Latino (six loci), or trans-ethnic (nine loci) ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). Only the *DNAH8/BTBD9* locus was suggestively significant in more than one race/ethnic group (rs862433 in African Americans, rs1950398 in Hispanic/Latinos). Only two of the suggestive SNPs were heterogeneous across populations with *P*~het~\<0.05 (rs4890550 and rs13223427).

Additionally, examination of 35 loci previously associated with QT in a published main effects GWAS([@R65]) found no significant associations in European descent populations using a Bonferroni corrected threshold of *P*\<0.001 (0.001=0.05/35; [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). The magnitude of the interaction effect was close to zero for all but six of the 35 SNP, which had interaction effects greater than 0.50 ms.

Similarly, while no locus showed genome-wide significance in our trans-ethnic MANTRA analysis ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}), one SNP (rs2765279) was above the suggestive threshold, with a log~10~(BF) of 5.2. Rs2765279, located in *RGSL1*, a gene involved in G-protein signaling regulation, was also the most significant SNP in the fixed-effects trans-ethnic analysis (*P*=3×10^−7^).

Genome-Wide Analysis of Thiazide-SNP Interaction and QRS Interval or JT Interval {#S12}
--------------------------------------------------------------------------------

Results for QRS showed a similar pattern to those for QT ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Whereas no results achieved genome-wide significance, 28 loci showed suggestive evidence of modifying the thiazide-QRS association (four loci in European descent populations, 11 in African Americans, eight in Hispanic/Latinos, and seven in trans-ethnic populations) and only one SNP had a *P*~het~\<0.05 (rs11591185). The most significant SNP, rs7638855 (*P*=2×10^−7^), located upstream from *GAP43*, was also suggestively significant after trans-ethnic analysis in MANTRA (log~10~(BF)=5.4; [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

Similarly, no SNPs showed genome-wide significant interaction for JT, although 19 loci were suggestively associated (five loci in European descent populations, four in African Americans, five in Hispanic/Latino, and seven in trans-ethnic populations; [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}, [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). No SNPs showed significant heterogeneity between populations. Moreover, MANTRA analysis identified two SNPs that achieved suggestive significance ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). The rs1264878 variant near *KCNIP4*, a voltage-gated potassium channel interacting protein was the most significant SNP in our fixed-effects meta-analyses (*P*=3×10^−7^) and had a log~10~(BF)=5.1. However, most significant SNP in MANTRA meta-analyses was rs9303589, in *CA10*, with a log~10~(BF)=5.1.

Cross-Phenotype Meta-Analysis {#S13}
-----------------------------

Cross-phenotype meta-analysis found no genome-wide significant evidence of pleiotropy across QRS and JT ([Figure 2](#F2){ref-type="fig"}, [Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). However, eight loci had a suggestive evidence of thiazide-SNP interaction after meta-analyzing QRS and JT results ([Table 3](#T3){ref-type="table"}). These included three loci that were nominally associated with QRS and JT (*P*\<0.05), but whose effects did not reach the suggestive association threshold in either univariate analysis (rs1295230 \[*PIK3R6*\], rs6931354 \[*ADGRB3*\], and rs8119517 \[*PREX1*\]).

Gene and Pathway Enrichment Analysis {#S14}
------------------------------------

Although analysis with DEPICT found no enrichment in a single gene or tissue, gene-set enrichment analysis in European descent populations found enrichment in the *ATXN3* subnetwork for the interactive effect of genotype and thiazide use on QT (*P=*1×10^−6^). There was no enrichment found in QRS or JT analyses. MAGMA analyses found significant enrichment in six genes among African Americans in the interactive effect of genotype and thiazide use on QRS: *CNTRL, CPN1, FAM65B, RAB14, ISY1, NELL1* ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}). No other MAGMA analyses found gene enrichment. MAGMA GSA for QT and JT analyses found significant enrichment for transcription and translational pathways, although no gene-set enrichment was found in QRS analyses ([Table 4](#T4){ref-type="table"}).

Statistical Power {#S15}
-----------------

Given the biologic plausibility of the suggestive results for all three traits, we examined statistical power for our analysis to assess our ability to detect interaction effects. Simulations demonstrated that all analyses were underpowered to detect thiazide-SNP interaction effects less than 3 ms (e.g. 15% power to detect an interactive effect of 2 ms; [Figure 3](#F3){ref-type="fig"}). However, even with time-varying drug exposure (i.e. observed QT measurement on and off drug within an individual), which demonstrated the greatest power, analyses for SNPs with MAF=5% did not achieve 80% power until the thiazide-SNP interaction effect reached 6 ms.

Discussion {#S16}
==========

In this study, we examined 78,199 participants of European, African American, or Hispanic/Latino descent for evidence of thiazide-SNP interactions influencing QT. Although we used a comprehensive approach that considered multi-ethnic populations, leveraged pleiotropy, accommodated population heterogeneity, and examined QT as well as its component parts (QRS, JT), we did not identify any genome-wide significant SNPs modifying the association between thiazides and these ECG intervals. However, we identified 74 loci with suggestive evidence of association through either univariate or cross-phenotype analyses as well as evidence of enrichment in pathways involved in transcription and translation.

Interestingly, our suggestive results included multiple loci involved in ion transport and handling, the disruption of which is believed to be an underlying mechanism in drug-induced QT prolongation,([@R66]) supporting the hypothesis that common SNPs modify the thiazide-QT relationship. For example, the *NELL1* locus was previously associated with changes in fasting plasma triglyceride levels in response to hydrochlorothiazide use.([@R67]) Other interesting suggestive results include the *PITX2* and *RYR3* QRS loci identified in Hispanic/Latinos, which may directly regulate ion channel genes and genes involved in calcium handling.([@R68]) Moreover, we found suggestive evidence of thiazide-SNP interactions on QT, QRS, or JT in other genes involved in ion transport and handling, including *STC2,*([@R69]) *EDN1,*([@R70]) *TRPC7,*([@R71]) *PKP2,*([@R72]) and *DISC1,*([@R73]) as well as a voltage-gated potassium channel gene (*KCNQ3*).

Despite these intriguing results, our power simulations suggested there was limited power to detect interaction effects of 2 ms, sizes consistent with QT main effects analyses.([@R65]) The low power suggests that larger sample sizes and/or innovative statistical methods may be required to study gene-environment interactions given the stringent genome-wide significance threshold.([@R74]--[@R76]) Furthermore, our power simulations demonstrated insufficient power to detect interaction effects of 5 ms or less for less common SNPs (MAF=5%). Therefore, future work should utilize larger sample sizes, particularly studies with longitudinal data, if available.

Another limitation of our work was that medication use data were collected infrequently, e.g. years apart. Particularly, medication assessments covered only one to two weeks of medication use in most participating cohorts and variables such as medication dosage and duration of use were not available universally across studies. Previous work has demonstrated a dose-dependent relationship between thiazide use and cardiac arrest, a potential outcome of QT prolongation.([@R77]) However, we were unable to identify participants using high dose thiazides because medication dosage data was unavailable in all cohorts. Furthermore, K^+^ measurements and information on K^+^ supplements was not obtained across all cohorts so we were unable to adjust for K^+^ levels in our analyses, despite the known role of thiazide diuretics in inducing hypokalemia and the role of hypokalemia in causing QT prolongation.([@R78], [@R79])

Furthermore, ECG intervals are known to vary in the presence of cardiovascular disease (CVD).([@R80]) While we did exclude participants with certain types of CVD including prevalent heart failure and atrial fibrillation, we were not able to further characterize the role of CVD in the pharmacogenomics of thiazide use and QT duration. Given that we saw larger mean QT and JT intervals in Hispanic/Latino populations than in European descent or African American populations in our study sample, as well a substantial difference in mean exposure to thiazides, ranging from just 9% in Hispanic/Latinos to 37% in African Americans, our analyses are limited by the heterogeneity of exposure and outcome in our population. The large difference in thiazide exposure between race/ethnic groups could also indicate an underlying difference in CVD prevalence among our populations. Considering that pharmacogenomic studies such as this one are already limited in their power to detect effects, the addition of unmeasured heterogeneity such as CVD status could further reduce our power to detect genetic effects modifying the relationship between thiazides and QT. Therefore, future work should consider alternate study designs, such as clinical trials or specially collected cohorts, as settings for pharmacogenomics work. In clinical trials or specialty cohorts, populations can be more closely controlled and therefore more homogeneous in traits that may confound the relationship between thiazides and QT.

Additionally, observational cohort studies are known to be susceptible to selection biases, such as prevalent user bias, whereby long-term medication users are least likely to suffer from ADRs and users with ADRs often stop therapy and therefore have a lower chance of being seen while on therapy.([@R81], [@R82]) Unfortunately, without information on duration of use, it is difficult to evaluate the effect of prevalent user bias on study results. Indeed, it is unclear if these biases are of concern in pharmacogenomic studies.([@R83], [@R84]) Additional work is needed to assess whether selection bias requires more consideration in pharmacogenomic research and to assess possible advantages of alternative designs, such as active comparator designs (whereby the control group contains participants using a different class of medications with similar indications to the medication of interest) or new user designs (whereby prevalent users are excluded). Moreover, medication inventories may be associated with non-negligible measurement error. For example, while Smith *et al*. reported good agreement between thiazide use measured using medication inventories and serum thiazide measurements, specificity remained moderate. ([@R85])

Given the challenges associated with assembling an adequately powered pharmacogenomics study, electronic medical records (EMRs) represent a potential untapped resource that may merit evaluation. Strengths of EMRs include the potential to provide a more complete medication history, which could enable sensitivity analyses examining variables such as medication dose and duration of use. Furthermore, consortia such as eMERGE have demonstrated the feasibility of linking EMRs to genetic data for use in genetic research,([@R86]) and have successfully identified genetic variants modifying drug response.([@R87]) However, EMRs have limitations. Investigators using EMR data cannot control participant recruitment, timing and accuracy of data collection, or population representativeness.([@R88]) Considering ECG research specifically, cohort studies administer ECGs to all participants at study visits, whereas EMRs may capture ECGs for patients with medical indications, providing an inherently different population. EMRs therefore have the potential to greatly advance pharmacogenomic research but warrant further evaluation.

In conclusion, our findings suggest that additional work is needed to fully elucidate potential pharmacogenomic effects influencing the thiazide-QT relationship. Our suggestive results support a possible role of genetics in modifying the association between thiazides and QT. However, these findings can inform the biology of thiazide-induced QT-prolongation and do not preclude the possibility of common variants with small effects or rare variants with larger effects. Future work that leverages larger sample sizes, such as those available in EMRs, and innovative statistical methods to validate these suggestive findings is needed. The FDA considers further regulation of drugs that prolong QT by as little as 5 ms, a small increment easily achieved by the combination of genetic and pharmaceutical effects,([@R37], [@R89]) making it critical that we unravel the complex etiology of drug-induced QT prolongation.([@R90]) Pharmacogenomics remain a promising avenue for understanding variability in drug response and for utilizing genetics to improve public health but innovative solutions are needed to overcome inherent challenges.
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![Manhattan plots of *P*-values for thiazide-SNP interaction estimates for QT interval analyses after fixed effects meta-analysis among European descent populations (N = 51,601), African American populations (N = 11,482), Hispanic/Latino populations (N = 15,116), and all populations (trans-ethnic). Each study was analyzed using linear regression, mixed-effects models, or generalized estimating equations and SNPs with a study-specific degree of freedom measure (df = twice the cohort- and SNP-specific product of the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide \[N*~exposed~*\]) \< 15 were excluded from meta-analysis. The x-axis represents the chromosomal position and the y-axis represents the −log~10~(*P-*value). On each plot, genome wide significance (*P* \< 5×10^−8^) and suggestive significance (*P* \< 5×10^−6^) are denoted with dashed lines.](nihms859114f1){#F1}

![Manhattan plots of *P*-values thiazide-SNP interaction estimates after cross-phenotype meta-analysis (QRS interval, JT interval) using aSPU among European descent populations (N = 47,836), African American populations (N = 11,482), and Hispanic/Latino populations (15,116). For each trait separately, each study was analyzed using linear regression, mixed-effects models, or generalized estimating equations and SNPs with a study-specific degree of freedom measure (df = twice the cohort- and SNP-specific product of the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide \[N*~exposed~*\]) \< 15 were excluded from cross-phenotype meta-analysis. The x-axis represents the chromosomal position and the y-axis represents the −log~10~(*P-*value). On each plot, genome wide significance (*P* \< 5×10^−8^) and suggestive significance (*P* \< 5×10^−6^) are denoted with dashed lines.](nihms859114f2){#F2}

![Statistical power of a simulated pharmacogenomics study of QT. The x-axis represents the range of tested drug-SNP interaction effects in milliseconds (ms). The y-axis represents the power to detect the tested drug-SNP interaction effect. The following assumptions were used for the calculations: 2 serial visits measuring electrocardiograms (ECGs) and drug exposure, N=50,000 participants, a single-nucleotide polymorphism (SNP) minor allele frequency (MAF) of 5% or 25%, and the *N*~exposed~ = 8,100. Simulation analyses were run using only the baseline visit (cross-sectional) and a longitudinal model. Under the longitudinal model, simulations were run with all participants having constant drug exposure across visits or having varied drug exposure across visits. Cross-sectional models were run using linear regression and longitudinal models were run using a generalized estimating equation with an independence working correlation.](nihms859114f3){#F3}

###### 

Study Population Characteristics of 25 Contributing Study Populations

  Population                                   N~exposed~   N~total~   QT in ms, mean (SD)   QRS in ms, mean (SD)   JT in ms, mean (SD)   Age in years, mean (SD)   Female, %
  -------------------------------------------- ------------ ---------- --------------------- ---------------------- --------------------- ------------------------- -----------
  **European Descent**                                                                                                                                              
   AGES                                        435          2,256      405 (34)              90 (10)                316 (33)              75 (5)                    64.2
   ARIC                                        1,449        8,567      399 (29)              91 (10)                308 (29)              54 (6)                    52.6
   CHS                                         1,003        3,004      414 (32)              88 (10)                322 (30)              72 (5)                    62.5
   ERF                                         29           1,792      398 (28)              NA                     NA                    48 (14)                   59.0
   FHS                                         83           3,168      415 (30)              88 (10)                328 (30)              40 (9)                    52.5
   H2000                                       104          1,973      389 (30)              NA                     NA                    50 (11)                   52.0
   Health ABC                                  217          1,560      414 (32)              90 (11)                324 (32)              74 (3)                    49.4
   MESA                                        453          2,216      412 (29)              93 (9)                 320 (29)              62 (10)                   52.1
   NEO                                         609          5,366      406 (29)              93 (10)                313 (29)              56 (6)                    47.0
   PROSPER                                     1,175        4,556      414 (36)              94 (11)                320 (35)              75 (3)                    47.0
   RS I                                        523          4,805      397 (29)              97 (11)                300 (28)              69 (9)                    60.2
   RS II                                       161          1,889      403 (28)              98 (11)                305 (28)              65 (8)                    56.6
   RS III                                      93           1,950      401 (26)              98 (11)                304 (26)              56 (6)                    54.1
   WHI GARNET[a](#TFN2){ref-type="table-fn"}   431          1,981      401 (29)              86 (9)                 315 (29)              66 (7)                    100
   WHI MOPMAP[a](#TFN2){ref-type="table-fn"}   268          1,383      402 (30)              86 (8)                 316 (30)              63 (7)                    100
   WHI WHIMS[a](#TFN2){ref-type="table-fn"}    1,106        5,135      401 (30)              86 (9)                 315 (29)              68 (6)                    100
   Summary                                     8,139        51,601                                                                                                  
  **African American**                                                                                                                                              
   ARIC                                        916          2,169      400 (33)              90 (10)                310 (32)              53 (6)                    62.3
   CHS                                         351          666        409 (35)              88 (11)                317 (36)              73 (6)                    64.4
   Health ABC                                  268          1,151      411 (35)              88 (11)                322 (34)              73 (3)                    57.6
   JHS                                         463          1,862      410 (32)              92 (10)                319 (30)              50 (12)                   60.9
   MESA                                        467          1,464      410 (32)              91 (10)                319 (31)              62 (10)                   54.4
   WHI SHARe                                   1,661        4,170      401 (34)              85 (9)                 316 (33)              61 (7)                    100
   Summary                                     4,215        11,482                                                                                                  
  **Hispanic/Latino**                                                                                                                                               
   HCHS/SOL                                    941          12,024     416 (28)              91 (10)                325 (29)              46 (14)                   59.5
   MESA                                        211          1,316      409 (30)              91 (10)                318 (30)              61 (10)                   51.8
   WHI SHARe                                   224          1,776      401 (30)              86 (9)                 316 (30)              60 (6)                    100
   Summary                                     1,376        15,116                                                                                                  

Abbreviations: AGES, Age, Gene/Environment Susceptibility -- Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; Health ABC, Health, Aging, and Body Composition Study; JHS, Jackson Heart Study; JT, JT interval; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; N~exposed~, Number of participants exposed to thiazides; N~total~, Total number of participants in study population after exclusions; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QRS, QRS interval; QT, QT interval; RS, Rotterdam Study; SD, Standard deviation; SHARe, The SNP Health Association Resource; WHI, Women's Health Initiative; WHIMS, the WHI Memory Study

Participants overlapping between GARNET, MOPMAP, and WHIMS were excluded from analyses to prevent lack of independence

###### 

Loci with Suggestive Evidence of Association with the Thiazide-SNP Interaction Effect on QT Interval

  Locus                  SNP          Chr   Position[a](#TFN4){ref-type="table-fn"}   CA   CAF    Interaction Effect in ms (SE)   *P*        *P*~het~
  ---------------------- ------------ ----- ----------------------------------------- ---- ------ ------------------------------- ---------- ----------
  **European Descent**                                                                                                                       
  *KIAA2013*             rs17367934   1     11890791                                  A    0.89   2.4 (0.5)                       2×10^−6^   0.9
  *SLC14A2*              rs4890550    18    41409189                                  C    0.44   −1.4 (0.3)                      3×10^−6^   0.01
  *RPS29*                rs10143493   14    47999650                                  A    0.01   −10.6 (2.3)                     3×10^−6^   0.4
  *NELL1*                rs12225793   11    21057283                                  T    0.12   2.3 (0.5)                       4×10^−6^   1.0
  *STC2*                 rs10079004   5     172704698                                 A    0.71   −1.5 (0.3)                      4×10^−6^   0.4
  *LCLAT1*               rs7608507    2     30447424                                  A    0.75   1.6 (0.3)                       4×10^−6^   0.7
  *PPP1R3A*              rs13223427   7     113199332                                 T    0.56   1.4 (0.3)                       4×10^−6^   0.02
  **African American**                                                                                                                       
  *ZBTB16*               rs10789991   11    113424299                                 T    0.03   12.3 (2.4)                      5×10^−7^   0.6
  *DNAH8*                rs862433     6     38968057                                  A    0.25   −2.6 (0.5)                      7×10^−7^   0.2
  *Intergenic*           rs9376483    6     140352934                                 T    0.94   7.2 (1.4)                       7×10^−7^   0.5
  *CASP8AP2*             rs7753194    6     90597484                                  A    0.02   −11.4 (2.4)                     3×10^−6^   0.2
  *EBF1*                 rs11135035   5     157833407                                 A    0.41   2.1 (0.5)                       4×10^−6^   0.9
  *LAMA4*                rs6926485    6     112630302                                 T    0.64   2.4 (0.5)                       5×10^−6^   0.5
  **Hispanic/Latino**                                                                                                                        
  *SPDYA*                rs12475612   2     28883510                                  T    0.48   −3.5 (0.7)                      1×10^−6^   0.9
  *BTBD9*                rs1950398    6     38666897                                  T    0.97   9.6 (2.0)                       2×10^−6^   0.05
  *TDRP*                 rs6558894    8     480495                                    C    0.14   −4.9 (1.0)                      2×10^−6^   0.3
  *COLCA2*               rs10749974   11    110696967                                 A    0.09   −6.0 (1.3)                      3×10^−6^   0.2
  *CRYGGP*               rs17868255   2     51884417                                  A    0.97   10.3 (2.2)                      3×10^−6^   0.5
  *RYR3*                 rs16968694   15    31376213                                  A    0.18   4.5 (1.0)                       3×10^−6^   1.0
  **Trans-Ethnic**                                                                                                                           
  *RGSL1*                rs2765279    1     180693520                                 T    0.28   1.4 (0.3)                       3×10^−7^   0.4
  *ZBTB16*               rs10789991   11    113424299                                 T    0.03   12.3 (2.4)                      5×10^−7^   0.6
  *PPP1R3A*              rs17619887   7     113142601                                 A    0.47   1.2 (0.3)                       2×10^−6^   0.07
  *KIAA2013*             rs17367934   1     11890791                                  A    0.89   2.3 (0.5)                       2×10^−6^   1.0
  *LCLAT1*               rs6756908    2     30446501                                  A    0.65   1.3 (0.3)                       2×10^−6^   0.5
  *FAR1*                 rs7130476    11    13711632                                  C    0.90   2.0 (0.4)                       3×10^−6^   0.5
  *CASP8AP2*             rs7753194    6     90597484                                  A    0.02   −11.4 (2.4)                     3×10^−6^   0.2
  *SMARCA2*              rs1886261    9     2163590                                   A    0.75   1.5 (0.3)                       3×10^−6^   0.9
  *ZKSCAN8*              rs13205911   6     28232093                                  T    0.09   −2.5 (0.5)                      5×10^−6^   0.6

Abbreviations: CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; *P*, *P*-value; *P*~het~, *P*-value of heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism

Build 36 Base-Pair Position

###### 

Loci with Suggestive Evidence Modifying the Effect of Thiazide on QRS and JT Intervals After Cross-Phenotype Meta-Analysis

  Locus                  SNP          Chr   Position[a](#TFN6){ref-type="table-fn"}   CA   CAF    *P*        Univariate *P*-value   
  ---------------------- ------------ ----- ----------------------------------------- ---- ------ ---------- ---------------------- ----------
  **European Descent**                                                                                                              
  *PIK3R6*               rs1295230    17    8682305                                   T    0.02   3×10^−6^   0.008                  0.001
  **African American**                                                                                                              
  *ADGRB3*               rs6931354    6     69527128                                  A    0.21   1×10^−7^   0.005                  0.0002
  *ADCY8*                rs10108730   8     131767803                                 T    0.79   2×10^−6^   1×10^−5^               0.0003
  *PREX1*                rs8119517    20    46464282                                  A    0.94   3×10^−6^   0.0005                 0.02
  *CDH13*                rs11649358   16    81415652                                  A    0.75   5×10^−6^   9×10^−6^               0.001
  **Hispanic/Latino**                                                                                                               
  *AK2*                  rs11591185   1     33274771                                  A    0.07   2×10^−6^   7×10^−7^               3×10^−5^
  *ASS1P14*              rs12578228   12    33030528                                  T    0.10   2×10^−6^   2×10^−6^               2×10^−5^
  *GALNT13*              rs17553946   2     155055407                                 A    0.23   4×10^−6^   0.005                  9×10^−7^

Abbreviations: CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; JT, JT interval; *P*, *P*-value; QRS, QRS interval; SE, Standard error; SNP, Single nucleotide polymorphism

Build 36 Base-Pair Position

###### 

Gene-Sets with Enrichment for Genotype-Thiazide Interaction Effects

  Trait                                                                      Population                                Gene-Set                             *P*        FDR
  -------------------------------------------------------------------------- ----------------------------------------- ------------------------------------ ---------- -------
  QT                                                                         Hispanic/Latino                           Nucleotide Binding                   5×10^−6^   0.004
  Metal Ion Binding                                                          6×10^−6^                                  0.004                                           
  tRNA Adenine-N1 Methyltransferase Activity                                 6×10^−5^                                  0.03                                            
  Transcription Coactivator Activity                                         8×10^−5^                                  0.03                                            
  Transcriptional Activity of SMAD2, SMAD3, SMAD4, Heterotrimer              0.0001                                    0.03                                            
  Zinc Ion Binding                                                           0.0002                                    0.04                                            
  Other RNA Binding Protein                                                  0.0002                                    0.04                                            
  Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPS/IMPS/VICKZS)   0.0003                                    0.05                                            
  Trans-Ethnic                                                               General RNA Polymerase II Transcription   4×10^−6^                             0.006      
  Transcription                                                              4×10^−5^                                  0.03                                            
  JT                                                                         African American                          Transcription Factor TFIID Complex   7×10^−5^   0.05
  Aminoacyl-tRNA Synthetase Multienzyme Complex                              0.0001                                    0.05                                            
  tRNA Aminoacylation for Protein Translation                                0.0001                                    0.05                                            
  Transcription Factor TFTC Complex                                          0.0001                                    0.05                                            
  Trans-Ethnic                                                               Transciption                              3×10^−5^                             0.03       
  General RNA Polymerase II Transcription Factor Activity                    4×10^−5^                                  0.03                                            

Abbreviations: FDR, False discovery rate; JT, JT interval; *P*, *P*-value; QT, QT interval
